More Than a CDMO
The End-to-End Support of Your Portfolio
Pre-Clinical
Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.
Clinical Phase I, II
Partner with us to develop your initial clinical process for cGMP drug substance and drug product manufacturing.
Clinical Phase III
Partner with us to optimize, scale and characterize your process to meet anticipated therapeutic demands.
Commercialization
Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.
Setting New Standards in Tomorrow’s Medicines
0
Billion USD Invested
in recent years
Spotlight
Press Releases
FUJIFILM Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion
HOLLY SPRINGS, N.C., April 22, 2025 – FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to provide U.S.-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
Press Releases
FUJIFILM Biotechnologies Celebrates Opening of the Latest Manufacturing Expansion – a Major Boost to Danish Life Science
HILLERØD, DENMARK, January 9, 2025 — The Danish life science industry is getting yet another boost as FUJIFILM Biotechnologies celebrates its recent production expansion in Denmark.
Press Releases
FUJIFILM Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility
THOUSAND OAKS, CALIF., November 20, 2024 – FUJIFILM Biotechnologies today hosted a celebration for the completion of an expansion of its cell therapy manufacturing facility in Thousand Oaks, California.
